Founded the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London; designed a number of functional brain imaging studies with psilocybin (magic mushrooms), LSD, MDMA (ecstasy) and DMT (ayahuasca), plus a clinical trial of psilocybin for treatment resistant depression. 2019, team hopes to complete a clinical trial of psilocybin versus escitalopram for major depressive disorder plus another study looking at the longer-term brain effects of psilocybin in healthy volunteers. Also in 2019, will Found a new Centre for Psychedelic Research at the University of Oxford.